Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of newly diagnosed unresectable stage IIIB or IV NSCLC in China
ChiCTR-OCH-14004843Phase 4Completed
- Sponsor
- NA
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by NA. Primary endpoints: progression-free survival and overall survival. Started Aug 2014; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OCH-14004843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCH-14004843.